Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The economic burden of moderate-to-severe rheumatoid arthritis in Spain: the CIARA study.

Journal of medical economics·2026
Same author

UV Protection Habits and Preferences in Patients With Distinct Cutaneous Immune-Mediated Inflammatory Diseases.

Photodermatology, photoimmunology & photomedicine·2026
Same author

Discordant Patch Test Reactions to 2-Bromo-2-Nitro-Propane-1,3-Diol (Bronopol): A Multicenter Study From REIDAC.

Contact dermatitis·2025
Same author

Do Allergic Comorbidities Alter the Efficacy and Safety of Abrocitinib or Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis?

Dermatology and therapy·2025
Same author

Severe Oral Lichen Planus Masking a Primary Immunodeficiency: X-Linked Lymphoproliferative Disease Type 1 (XLP-1).

Pediatric dermatology·2025
Same author

The Changing Spectrum of Pediatric Allergic Contact Dermatitis: A Prospective Multicentric Study in Spain.

Dermatitis : contact, atopic, occupational, drug·2025

Related Experiment Video

Updated: Jun 19, 2026

Precision Implementation of Minimal Erythema Dose (MED) Testing to Assess Individual Variation in Human Inflammatory Response
06:31

Precision Implementation of Minimal Erythema Dose (MED) Testing to Assess Individual Variation in Human Inflammatory Response

Published on: October 3, 2019

Quantifying Physician Preferences for Systemic Atopic Dermatitis Treatments Using a Discrete-Choice Experiment.

José Manuel Carrascosa Carrillo1, Eulalia Baselga Torres2, Yolanda Gilaberte Calzada3

  • 1Hospital Universitari Germans Trias i Pujol, Carretera de Canyet, s/n, Badalona, 08916, Barcelona, Spain.

Dermatology and Therapy
|April 21, 2022
PubMed
Summary

Physicians prioritize clinical efficacy and safety when selecting systemic treatments for moderate-to-severe atopic dermatitis (AD). They accept some adverse events for better symptom relief and long-term benefits, guiding optimal therapy choices.

Keywords:
Atopic dermatitisDiscrete-choice experimentMaximum acceptable riskPhysician preference

More Related Videos

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

Measuring Psoriasis Severity at Home
02:28

Measuring Psoriasis Severity at Home

Published on: March 1, 2024

Related Experiment Videos

Last Updated: Jun 19, 2026

Precision Implementation of Minimal Erythema Dose (MED) Testing to Assess Individual Variation in Human Inflammatory Response
06:31

Precision Implementation of Minimal Erythema Dose (MED) Testing to Assess Individual Variation in Human Inflammatory Response

Published on: October 3, 2019

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

Measuring Psoriasis Severity at Home
02:28

Measuring Psoriasis Severity at Home

Published on: March 1, 2024

Area of Science:

  • Dermatology
  • Pharmacology
  • Clinical Research

Background:

  • Emerging treatments for moderate-to-severe atopic dermatitis (AD) necessitate understanding physician preferences.
  • Identifying factors influencing treatment selection is crucial for optimizing patient care.

Purpose of the Study:

  • To explore physician preferences for systemic treatments in moderate-to-severe AD.
  • To identify sociodemographic factors influencing these preferences.
  • To evaluate physician satisfaction with current AD therapies.

Main Methods:

  • A discrete-choice experiment (DCE) survey was conducted with physicians treating AD in Spain.
  • Conditional logit modeling was used to analyze attribute importance and risk tolerance.

Main Results:

  • Clinical efficacy and risk of severe adverse events (AEs) were paramount.
  • Improvements in sleep and pruritus, and rapid onset of action were highly valued.
  • Physicians accepted increased risk of AEs for enhanced efficacy and long-term benefits.

Conclusions:

  • Findings aid prescribers in selecting optimal systemic therapies for moderate-to-severe AD.
  • Understanding physician priorities can guide the development and positioning of new AD treatments.